Humanwell Healthcare (600079.SH): The application for the market approval of fentanyl citrate oral patches has been accepted.

Humanwell Healthcare (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. ("Yichang Renfu", in which the company holds 80% of its shares) recently received the approval and issuance of the registration and listing application for fentanyl citrate oral patches by the National Medical Products Administration. It is reported that fentanyl citrate oral patches are used to treat breakthrough pain in adult cancer patients who are continuously using opioid drugs. Currently, there are no similar products on the market in China, with the only available products being fentanyl citrate injection and fentanyl transdermal patches. According to Minet data, the sales of all fentanyl formulations in urban, county, and township public hospitals in China are expected to reach approximately RMB 330 million by 2023.